jolt-ca

Joint Lung Cancer Trialist's Coalition

Newsletter for Clinical Trial Partners / September 2018

UTSouthwestern
Harold C. Simmons
Comprehensive Cancer Center
Radiation Oncology

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

STABLEMATES TRIAL



TIPS:

- ***Follow-up procedures***: If patients only agree to the follow-up portion of the study, the study calendar should still be followed (Section 9.5) with all procedures listed at the designated timepoints being completed by someone on the study team delegated to perform the procedures.
- Remember to upload eligibility checklist and consent within two business days of completion. Treatment and follow-up information should be entered within 30 days of the visit/end of treatment.
- If new personnel are going to be added to a subsite's study team, please notify Sarah Hardee Neufeld so she is aware.
- If errors need to be corrected, ensure that the corrections are initialed and dated.
- If a patient has an SAE (Section 11.4), fill out the SAE form on the Jolt webpage and submit to Sarah. All deaths need to be reported regardless of relatedness. If there are questions about whether or not something needs to be reported, please contact Sarah.
- Make sure the eligibility checklist is signed off by the appropriate parties to meet the criteria.
- Do not contact IROC for credentialing documentation. Instead, visit the Stablemates website at ***www.joltca.org.***

We hope everyone has received their JoLT T-shirts and is wearing them in celebration of the 100-patient milestone!*

**International sites: your T-shirts will be arriving shortly.*

jolt-ca

Joint Lung Cancer Trialist's Coalition

Newsletter for Clinical Trial Partners / SEPTEMBER 2018

SUBSITE UPDATE

Active:

- Anne Arundel Medical Center
- Boston University
- Cardiothoracic and Vascular Surgeons - Austin
- Case Western
- CHUM-Notre Dame Hospital
- Cleveland Clinic
- Henry Ford Health System
- INOVA
- Intermountain Medical Center
- Lifespan Oncology Clinical Research
- Medical College of Wisconsin
- Memorial Health University
- Meridian Health
- New York University
- Ochsner Medical Center
- Ohio State University
- Ottawa
- Penn State (Mount Nittany Medical Center)
- Penrose Cancer Center
- Providence Health and Services
- St. Vincent's – Australia
- SUNY
- Swedish Cancer Institute
- Thomas Jefferson University
- University of California San Diego
- UHN - Toronto General Hospital
- University of Cincinnati
- University of Colorado/Memorial
- University of Iowa
- University of Kansas
- University of Louisville Physicians
- University of North Carolina Chapel Hill
- UT Southwestern Medical Center
- University of Virginia
- West Clinic/University of Tennessee
- William Beaumont Hospital

Completed contracts:

- Sunnybrook

Completed IRB approval:

- CERV
- UPMC

If there are any questions regarding how to enter data-screen patients or any other aspect of the trial, please email or call Sarah.

Study Co-Chair & Surgery QA Study — Hiran Fernando, MD | hiran.fernando@inova.org | 703.776.3563
Co-Chair & Radiation QA — Robert Timmerman, MD | robert.timmerman@utsw.edu | 214.645.7651
Statistician — Chul Ahn, PhD | chul.ahn@utsw.edu | 214.648.9418
Clinical Research Coordinator — Sarah Hardee Neufeld, MS | sarah.hardee@utsw.edu | 214.648.1836
Research Manager — Sarmistha Sen, MS, MHA | sarmistha.sen@utsw.edu | 214.645.1477